Cure Hepatitis C Act of 2026

U.S. Congress · HR9682 · In Committee

Progression

Timing in context

Primary sponsor's contributions received (same period)

Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.

What the bill says

HR9682 · U.S. Congress · In Committee

Introduced 2026-07-14. Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

View on Congress.gov →

Summary (plain-language)

Cure Hepatitis C Act of 2026 This bill establishes programs and requirements to provide free medications to treat hepatitis C in certain high-risk or vulnerable populations. It also establishes grants and other resources to support testing and treatment for hepatitis C. The bill provides funding for FY2027 to implement these provisions. The Department of Health and Human Services (HHS) must enter into a five-year purchasing contract with manufacturers of drugs that treat hepatitis C so that eligible individuals may receive the drugs without cost-sharing. Eligible individuals are those diagnosed with hepatitis C who are (1) enrolled in Medicaid or the Children’s Health Insurance Program (CHIP), (2) confined to federal, state, or local correctional facilities (or were released and began treatment there), (3) uninsured, or (4) receiving health care through the Indian Health Service. State Medicaid and CHIP programs and state and local correctional facilities may opt into the program; participation is mandatory for federal correctional facilities and the Indian Health Service. HHS must award grants to certain entities, including states, public health organizations, and correctional facilities, to support the coordination and provision of screening, treatment, and supportive services for the affected populations. The bill also allows Medicare beneficiaries to receive hepatitis C drugs without cost-sharing from 2028-2032.

Sponsors

Text versions

  • Introduced in House — 2026-07-14 — XML

What analysts say

No nonpartisan analysis on file for this measure yet.

What politicians say

No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.

Action History

DateAction
2026-07-14Introduced in House
2026-07-14Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

← Back to legislation